IRIS
BERSANELLI, MELISSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.543
EU - Europa 1.482
AS - Asia 415
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.452
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.537
IE - Irlanda 584
SE - Svezia 441
CN - Cina 240
IT - Italia 180
SG - Singapore 129
AT - Austria 106
FI - Finlandia 46
DE - Germania 45
FR - Francia 18
BE - Belgio 17
CZ - Repubblica Ceca 14
IN - India 11
CI - Costa d'Avorio 10
TR - Turchia 10
GB - Regno Unito 8
NL - Olanda 8
IR - Iran 7
RU - Federazione Russa 6
VN - Vietnam 6
CA - Canada 5
HK - Hong Kong 5
JP - Giappone 3
KR - Corea 2
KZ - Kazakistan 2
UA - Ucraina 2
AU - Australia 1
BS - Bahamas 1
CH - Svizzera 1
EU - Europa 1
HR - Croazia 1
LU - Lussemburgo 1
MD - Moldavia 1
PL - Polonia 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.452
Salva come PNG Salva come JPEG
Città #
Dublin 578
Chandler 462
Ashburn 162
Princeton 113
Vienna 106
Shanghai 92
Ann Arbor 79
Singapore 67
Beijing 64
Helsinki 45
Boardman 39
New York 39
Bremen 28
Wilmington 26
Des Moines 24
Milan 19
Parma 18
Brussels 16
Chicago 15
Dearborn 12
Los Angeles 12
Abidjan 10
Bologna 10
Rome 10
Seattle 10
Brno 9
Nanjing 9
Verona 8
Borås 7
Fremont 7
Rio Saliceto 7
Dong Ket 6
Fairfield 6
Houston 6
Jinan 6
Modena 6
San Mateo 6
Izmir 5
Menlo Park 5
Pune 5
Tianjin 5
Woodbridge 5
Ardea 4
Hong Kong 4
Kish 4
Kocaeli 4
Kunming 4
London 4
Olomouc 4
Redwood City 4
Washington 4
Wayne 4
West Jordan 4
Changsha 3
Deiva Marina 3
Hebei 3
Hefei 3
Huizen 3
Leipzig 3
Macomer 3
Nanchang 3
Padova 3
Pavia 3
Phoenix 3
Reggio Emilia 3
Rockville 3
Sala Baganza 3
Shenyang 3
Stockholm 3
Taiyuan 3
Wuhan 3
Yangzhou 3
Zhengzhou 3
Alcamo 2
Almaty 2
Atlanta 2
Bagnolo in Piano 2
Bend 2
Bisceglie 2
Boston 2
Buffalo 2
Calvi Risorta 2
Daejeon 2
Delhi 2
Deventer 2
Falls Church 2
Florence 2
Fuzhou 2
Genoa 2
Guangzhou 2
Hangzhou 2
Huskvarna 2
Jacksonville 2
Munich 2
Ningbo 2
Norwalk 2
Nuremberg 2
St Petersburg 2
Taizhou 2
Torrile 2
Totale 2.322
Salva come PNG Salva come JPEG
Nome #
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 98
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 87
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 72
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 71
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 63
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 62
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 62
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 61
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 61
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 60
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients 54
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 53
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 52
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 52
The effect of COVID-19 emergency in the management of melanoma in Italy 51
Review on radiological evolution of COVID-19 pneumonia using computed tomography 50
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 50
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 49
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 49
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 47
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 47
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 46
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 46
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 45
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 44
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 44
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 42
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 42
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 41
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 41
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 41
The 'nivolution' in renal cell carcinoma: Behind the scenes of clinical trials 41
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 40
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 39
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 38
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 38
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? 37
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 37
Cabozantinib in RCC: only a METEOR or a rising star? 37
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 36
Avelumab Maintenance for Urothelial Carcinoma 35
Capter 4 - Adjuvant Therapy for Renal Cell Carcinoma 34
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 34
Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma 34
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 33
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 32
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 32
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 31
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 31
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 30
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 29
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 29
Renal cell carcinoma and viral infections: A dangerous relationship? 29
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 28
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 28
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis 28
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 27
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 27
Patient performance status and cancer immunotherapy efficacy: a meta-analysis 27
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) 27
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 27
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 26
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9) 25
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 25
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 25
Pathological nodal staging score for renal cell carcinoma: How to build reliable therapeutic choices basing on assumptions 25
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 24
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 24
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients 24
Pazopanib in renal cell carcinoma dialysis patients: A mini-review and a case report 23
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review 23
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 23
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? 23
Reassessing Human Adipose Tissue 23
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 21
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis 21
Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice? 21
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients 21
Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma 20
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer 20
Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials 19
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 19
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 19
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: Evidence to date 16
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma 15
Upfront chemohormonal therapy for prostate cancer: Neutropenia and G-CSF use 15
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak 15
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 15
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study 15
A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study 14
Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: A pooled analysis of 926 patients 14
Systemic adjuvant therapies in renal cell carcinoma 14
Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492 14
Combination therapy in kidney cancer: The next revolution? 14
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis 14
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? 14
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 14
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Part 2 - Prostate and bladder cancer 13
Is cabozantinib really better than sunitinib as first-line treatment of metastatic renal cell carcinoma? 13
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 13
Totale 3.394
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.399
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.399
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020182 18 22 11 0 6 18 13 16 10 45 21 2
2020/2021150 2 1 4 22 7 23 9 13 22 19 10 18
2021/2022541 11 14 13 24 6 3 160 45 28 6 40 191
2022/20231.984 239 222 118 123 146 224 12 99 691 13 71 26
2023/2024743 39 64 21 20 61 152 52 45 32 44 86 127
2024/202531 31 0 0 0 0 0 0 0 0 0 0 0
Totale 3.648